Recently, the 16th China Healthcare Summit of Entrepreneurs, Scientists, and Investors (CHSESI) was grandly held in Chengdu. The conference was organized by the China Pharmaceutical Enterprise Management Association (CPEA), the China Medicinal Biotechnology Association (CMBA), and the Sichuan Association of Pharmaceutical (SAPC), with co-hosting by Healthcare Executive and the China Healthcare Industry Investment 50 Forum (H50) . During the conference, the “2024 Top 100 Chinese Pharmaceutical Innovation Enterprises” list (CPIE 100), ASK was once again selected.
The list is based on data from Healthcare Executive utilizing Derwent Innovation? patent data and Cortellis? competitive intelligence and clinical trial data, evaluated through a "three-dimensional, four-indicator" selection system. After data screening and comprehensive analysis, it showcases the efforts of all participants in the fierce competition of innovation within China's pharmaceutical industry. The “CPIE 100” represents the foremost force in China’s pharmaceutical innovation capabilities. As a mature pharmaceutical manufacturing enterprise driven by innovation and research and development, ASK actively responds to challenges in the industry and market, adhering to the business philosophy of “Research as the Source, Health as the Foundation.” The company targets unmet clinical needs and accelerates the development of new drugs in four therapeutic areas: digestive, anti-tumor, anti-infection, and chronic diseases, with 11 key innovative chemical and biological drugs currently in clinical phases I-III, ready to enter a period of transformative innovation.
This year, ASK has continuously incubated advantageous projects through independent innovation capabilities, including the approval and launch of six new products, including the first class 2 modified new drug, Aolirui (Dexlansoprazole for Injection). At the same time, ASK persists in open innovation and collaborative progress, leveraging a talent chain to empower the industrial and innovation chains, establishing a collaborative innovation mechanism that integrates medicine, production, education, and research. The company explores high-quality pathways for translating clinically valuable results into real-world applications, having jointly developed groundbreaking molecular entities, the third-generation EGFR inhibitor ASK120067 tablets, and novel peptide drugs for combating drug-resistant infections, such as the injection form of ASK0912, aiding in the scientific governance of major diseases and public health issues in China.
Looking ahead, ASK will persist in its mission of “For Health, Healthy Actions” to continue advancing scientific and technological innovation. The focus will be on the research and development of small-molecule targeted innovative drugs and tumor immunobiologics, accelerating the conversion of innovative results into productive real-world applications to promote high-quality enterprise development and safeguard the health and lives of the people.